Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eidos Therapeutics Inc (EIDX)

Eidos Therapeutics Inc (EIDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,422,985
  • Shares Outstanding, K 36,884
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,290 K
  • 60-Month Beta -1.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.45
  • Number of Estimates 4
  • High Estimate -0.41
  • Low Estimate -0.51
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -55.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.34 +10.18%
on 10/01/19
49.72 -26.11%
on 09/19/19
-8.26 (-18.37%)
since 09/13/19
3-Month
28.00 +31.20%
on 08/05/19
49.72 -26.11%
on 09/19/19
-3.24 (-8.09%)
since 07/12/19
52-Week
9.03 +306.81%
on 10/17/18
49.72 -26.11%
on 09/19/19
+27.39 (+292.89%)
since 10/12/18

Most Recent Stories

More News
BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed...

BBIO : 18.51 (-0.11%)
EIDX : 36.77 (-4.69%)
Alexion (ALXN) Collaborates With Stealth BioTherapeutics

Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

AMGN : 204.39 (+1.79%)
ALXN : 101.80 (+2.57%)
EIDX : 36.77 (-4.69%)
MITO : 6.97 (-2.52%)
Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced...

EIDX : 36.77 (-4.69%)
Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3 at 3:00 p.m. EDT in New York, NY.

EIDX : 36.77 (-4.69%)
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019

Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.

BIIB : 225.92 (+1.21%)
ALXN : 101.80 (+2.57%)
AMGN : 204.39 (+1.79%)
EIDX : 36.77 (-4.69%)
EIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims...

EIDX : 36.77 (-4.69%)
Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares

Eidos Therapeutics, Inc. (Nasdaq:EIDX) ("Eidos") announced today that the Special Committee of its Board of Directors (the "Special Committee") unanimously rejected the non-binding proposal dated August...

EIDX : 36.77 (-4.69%)
Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan

Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.

AMGN : 204.39 (+1.79%)
ALXN : 101.80 (+2.57%)
BBIO : 18.51 (-0.11%)
EIDX : 36.77 (-4.69%)
Alexion and BridgeBio Announce Japanese License Agreement for Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

--- Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to initiate in second half of 2019 -

ALXN : 101.80 (+2.57%)
BBIO : 18.51 (-0.11%)
EIDX : 36.77 (-4.69%)
Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. and Encourages Investors to Contact the Firm - EIDX

Kaskela Law LLC is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ: EIDX) on behalf of the company's shareholders.

EIDX : 36.77 (-4.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade EIDX with:

Business Summary

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.

See More

Key Turning Points

2nd Resistance Point 40.63
1st Resistance Point 39.60
Last Price 36.77
1st Support Level 37.65
2nd Support Level 36.72

See More

52-Week High 49.72
Last Price 36.77
Fibonacci 61.8% 34.18
Fibonacci 50% 29.37
Fibonacci 38.2% 24.57
52-Week Low 9.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar